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abstract
PURPOSE As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy
would benefit patients and healthcare providers.
PATIENTS AND METHODS Four of the six studies in the International Duration of Adjuvant Chemotherapy (IDEA)
collaboration included patients with high-risk stage II colon and rectal cancers. Patients were treated (clinician
and/or patient choice) with either fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and
oxaliplatin (CAPOX) and randomly assigned to receive 3- or 6-month treatment. The primary end point
is disease-free survival (DFS), and noninferiority of 3-month treatment was defined as a hazard ratio (HR)
of, 1.2- v 6-month arm. To detect this with 80% power at a one-sided type one error rate of 0.10, a total of 542
DFS events were required.
RESULTS 3,273 eligible patients were randomly assigned to either 3- or 6-month treatment with 62% receiving
CAPOX and 38% FOLFOX. There were 553 DFS events. Five-year DFS was 80.7% and 83.9% for 3-month and
6-month treatment, respectively (HR, 1.17; 80% CI, 1.05 to 1.31; P [for noninferiority] .39). This crossed the
noninferiority limit of 1.2. As in the IDEA stage III analysis, the duration effect appeared dependent on the
chemotherapy regimen although a test of interaction was negative. HR for CAPOX was 1.02 (80% CI, 0.88 to
1.17), and HR for FOLFOX was 1.41 (80% CI, 1.18 to 1.68).
CONCLUSION Although noninferiority has not been demonstrated in the overall population, the convenience,
reduced toxicity, and cost of 3-month adjuvant CAPOX suggest it as a potential option for high-risk stage II colon
cancer if oxaliplatin-based chemotherapy is suitable. The relative contribution of the factors used to define high-
risk stage II disease needs better understanding.
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INTRODUCTION
The addition of oxaliplatin to fluoropyrimidine has been
shown to improve the efficacy of adjuvant chemotherapy
treatment for patients with colon cancer.1-3 The initial two
studies included patients with stage II and stage III colon
cancer; in the MOSAIC study, 40% had stage II disease,
and in the NSABP CO-07 study, 28% of patients had
stage II disease.1,2 On the basis of these studies, 6-
month adjuvant treatment with fluorouracil, leucovorin,
and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin
(CAPOX) became the standard of care in this setting for
stage III colon cancer. However, it was recognized that
oxaliplatin resulted in significant cumulative and long-
lasting neurotoxicity, and as a result of this, six ran-
domized studies were launched to investigate whether
the duration of adjuvant chemotherapy treatment could
be reduced to 3 months to reduce toxicity, but without
compromising efficacy. International Duration of Adju-
vant Chemotherapy (IDEA), an academic collaboration,
was formed to prospectively analyze the individual pa-
tient data from these six studies to determine if treatment
duration could be shortened from 6 to 3 months. The
results for stage III colon cancer have been published.4
More recently, the practice of adjuvant chemotherapy
treatment for patients with high-risk stage II disease has
changed with single-agent fluoropyrimidine often given,
and while the hazard ratio (HR) for improvement in
disease-free survival (DFS) from the addition of oxaliplatin
is similar for stage II and stage III disease,1 in high-risk
stage II disease, overall survival (OS) was not improved by
the addition of oxaliplatin to fluoropyrimidine.5 Four of the
six studies in the IDEA collaboration included patients
with high-risk stage II disease as these studies were
conceived before the OS results of MOSAIC were known.
The results of the pooled analysis of the high-risk stage
II disease individual patient data from the four studies
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PATIENTS AND METHODS
Clinical Trials and Patients
IDEA was an academic collaboration of clinicians and
statisticians formed in 2006. All participants were involved
in the six concurrently running randomized phase III
clinical trials investigating the duration of adjuvant che-
motherapy treatment. Four of these trials such as Short
Course Oncology Treatment (SCOT) (ClinicalTrials.gov
identifier: NCT00749450; Current Controlled Trials num-
ber: ISRCTN59757862, and EudraCT number: 2007-
003957-10), Adjuvant Chemotherapy for Colon Cancer with
High Evidence2 (ACHIEVE2) (UMIN Clinical Trials Registry
number: UMIN000013036), Three or Six Colon Adjuvant
(TOSCA) (OsSC number: 2007-000354-31 and Clinical-
Trials.gov identifier: NCT0064660), and Hellenic Oncology
Research Group (HORG) (ClinicalTrials.gov identifier:
NCT01308086) recruited patients with high-risk stage II
colon and rectal cancer, and this analysis is of patients from
these four studies. All research Protocols (online only) were
approved by the relevant institutional review board or ethics
committee, and all patients provided written informed
consent. All four trials investigated whether 3-month ad-
juvant chemotherapy with an oxaliplatin and fluoropyr-
imidine doublet was noninferior to the then standard
duration of 6-month adjuvant chemotherapy treatment. In
all four studies, the choice of chemotherapy regimen, either
CAPOX or FOLFOX, was not randomized and decided by the
treating clinician before random assignment to 3-month or
6-month treatment. High-risk stage II disease was defined
as having one or more of the following adverse features: T4
disease, poorly differentiated adenocarcinoma, invasion
(vascular, perilymphatic, or perineural), inadequate nodal
harvest (defined as , 10 lymph nodes in SCOT and , 12
lymph nodes in TOSCA, HORG, and ACHIEVE2), bowel
obstruction, or perforation.6 The principles of data pooling
from these studies were agreed prospectively in a collab-
orative charter initially drawn up in 2011.
All studies recruited patients with colon cancer; SCOT also
recruited patients with rectal cancer. Details of the indi-
vidual trials are shown in Table 1. All four trials provided
individual patient data to the Independent Statistical Center
at the Mayo Clinic Rochester for analysis.
Statistical Design
A final statistical analysis plan was determined prior to the
analysis. The primary end point was DFS defined as the
time from the date of random assignment to the date of the
first recurrence, diagnosis of a second colon cancer, or
death from any cause, whichever occurred first. A modified
intention-to-treat (mITT) method was used to conduct the
primary analysis that included all patients who were ran-
domly assigned and had received at least one dose of
chemotherapy; a sensitivity analysis of the primary end
point was conducted restricted to the confirmed high-risk
stage II patients. Patients were analyzed as per their original
random assignment. The DFS HR and associated two-
sided CI were estimated by Cox regression analysis strat-
ified by study. The proportional hazards assumption for the
stratified Cox model was examined using scaled Schoen-
feld residuals. Q statistics and I2 values were used to assess
the potential heterogeneity of trial-specific DFS HRs
comparing 3 and 6 months of therapy. There was pre-
planned subgroup analysis for the duration effect by reg-
imen (CAPOX v FOLFOX), T stage (T4 v T1, 2, or 3) disease,
poorly differentiated tumors (yes/no), and inadequate nodal
harvest. An interaction P value , .1 was taken as statis-
tically significant after adjustment using the Benjamini-
Hochberg procedure for the tests conducted.
CONTEXT
Key Objective
Six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon
cancer. The International Duration of Adjuvant Chemotherapy (IDEA) collaboration has investigated if 3-month adjuvant
chemotherapy treatment can be given for colon cancer without compromising efficacy. We report the results from the four
IDEA studies that recruited high-risk stage II patients.
Knowledge Generated
Although noninferiority was not demonstrated for the overall study population (5-year disease-free survival of 80.7% and
83.9% for 3-month and 6-month treatments, respectively), the duration effect of adjuvant treatment is chemotherapy
regimen dependent, 6-month treatment results in significantly more toxicity, and these are in line with the results seen for
stage III disease. We have demonstrated that high-risk stage II colon cancers that are T4 or have two or more risk factors
have a worse prognosis.
Relevance
Three-month adjuvant capecitabine and oxaliplatin treatment can be considered an option for some patients with high-risk
stage II colon cancer.
2 © 2021 by American Society of Clinical Oncology
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Median (range) 63.0 (20, 82) 63.0 (23, 85) 65.0 (24, 82) 66.0 (23, 83) 64.0 (23, 84) 64.0 (20, 85) 64.0 (20, 85)
Missing 0 0 0 0 0 0 0
Sex, n (%)
Male 696 (54.9%) 635 (58.9%) 227 (55.0%) 292 (56.8%) 913 (55.7%) 937 (57.3%) 1850 (56.5%)
Female 571 (45.1%) 443 (41.1%) 186 (45.0%) 222 (43.2%) 725 (44.3%) 697 (42.7%) 1,422 (43.5%)
Missing 1 0 0 0 1 0 1
ECOG performance status, n (%)
0 1,208 (95.3%) 807 (74.9%) 355 (86.2%) 492 (95.7%) 1,428 (87.2%) 1,434 (87.8%) 2,862 (87.5%)
1 59 (4.7%) 271 (25.1%) 56 (13.6%) 22 (4.3%) 209 (12.8%) 199 (12.2%) 408 (12.5%)
2 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 1 (0.0%)
Missing 1 0 1 0 2 0 2
T stage, n (%)
T1 1 (0.1%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 2 (0.1%) 0 (0.0%) 2 (0.1%)
T2 11 (0.9%) 8 (0.7%) 0 (0.0%) 0 (0.0%) 8 (0.5%) 11 (0.7%) 19 (0.6%)
T3 950 (75.3%) 528 (49.0%) 356 (86.2%) 330 (64.2%) 1,081 (66.1%) 1,083 (66.4%) 2,164 (66.2%)
T4 300 (23.8%) 541 (50.2%) 57 (13.8%) 184 (35.8%) 544 (33.3%) 538 (33.0%) 1,082 (33.1%)
Missing 6 0 0 0 4 2 6
Number of lymph nodes examined
Median (range) 18.0 (0, 77) — 16.0 (2, 84) 23.0 (1, 74) 18.0 (0, 79) 18.0 (0, 84) 18.0 (0, 84)
Missing 20 1,078 0 0 553 545 1,098
Chemotherapy, n (%)
CAPOX 488 (38.5%) 783 (72.6%) 316 (76.5%) 432 (84.0%) 1,020 (62.2%) 999 (61.1%) 2019 (61.7%)
FOLFOX 780 (61.5%) 295 (27.4%) 97 (23.5%) 82 (16.0%) 619 (37.8%) 635 (38.9%) 1,254 (38.3%)
Missing 0 0 0 0 0 0 0
Rectal, n (%)
No 1,268 (100.0%) 948 (87.9%) 413 (100.0%) 514 (100.0%) 1,568 (95.7%) 1,575 (96.4%) 3,143 (96.0%)
Yes 0 (0.0%) 130 (12.1%) 0 (0.0%) 0 (0.0%) 71 (4.3%) 59 (3.6%) 130 (4.0%)
Missing 0 0 0 0 0 0 0
Poorly differentiated histology, n (%)
No 765 (61.4%) 820 (77.8%) 177 (42.9%) 455 (88.5%) 1,113 (68.8%) 1,104 (68.6%) 2,217 (68.7%)
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Yes 481 (38.6%) 234 (22.2%) 236 (57.1%) 59 (11.5%) 504 (31.2%) 506 (31.4%) 1,010 (31.3%)
Missing 22 24 0 0 22 24 46
Inadequate nodal harvest,a n (%)
No 923 (74.0%) 953 (90.3%) 291 (70.5%) 448 (87.2%) 1,308 (80.8%) 1,307 (81.1%) 2,615 (81.0%)
Yes 325 (26.0%) 102 (9.7%) 122 (29.5%) 66 (12.8%) 311 (19.2%) 304 (18.9%) 615 (19.0%)
Missing 20 23 0 0 20 23 43
Primary tumor obstruction, n (%)
No — 872 (83.0%) 372 (90.1%) 415 (80.7%) 842 (84.9%) 817 (82.9%) 1,659 (83.9%)
Yes — 179 (17.0%) 41 (9.9%) 99 (19.3%) 150 (15.1%) 169 (17.1%) 319 (16.1%)
Missing 1,268 27 0 0 647 648 1,295
Primary tumor perforation, n (%)
No — 895 (83.0%) 383 (92.7%) 481 (93.6%) 885 (88.1%) 874 (87.3%) 1759 (87.7%)
Yes — 183 (17.0%) 30 (7.3%) 33 (6.4%) 119 (11.9%) 127 (12.7%) 246 (12.3%)
Missing 1,268 0 0 0 635 633 1,268
Invasion (vascular, venous, lymphatic,
or perineural),b n (%)
No — 442 (42.5%) 185 (44.8%) 64 (12.5%) 358 (36.3%) 333 (33.9%) 691 (35.1%)
Yes — 599 (57.5%) 228 (55.2%) 450 (87.5%) 629 (63.7%) 648 (66.1%) 1,277 (64.9%)
Missing 1,268 37 0 0 652 653 1,305
Invasion (vascular, venous, or lymphatic), n (%)
No — 475 (45.4%) 186 (45.4%) 64 (12.5%) 376 (38.0%) 349 (35.6%) 725 (36.8%)
Yes — 571 (54.6%) 224 (54.6%) 450 (87.5%) 614 (62.0%) 631 (64.4%) 1,245 (63.2%)
Missing 1,268 32 3 0 649 654 1,303
Invasion (perineural), n (%)
No — 935 (91.8%) 343 (83.9%) — 644 (89.4%) 634 (89.7%) 1,278 (89.6%)
Yes — 83 (8.2%) 66 (16.1%) — 76 (10.6%) 73 (10.3%) 149 (10.4%)
Missing 1,268 60 4 514 919 927 1846
Abbreviations: ACHIEVE2, Adjuvant Chemotherapy for Colon Cancer with High Evidence2; CAPOX, capecitabine and oxaliplatin; ECOG, Eastern Cooperative Oncology Group; FOLFOX, fluorouracil,
leucovorin, and oxaliplatin; HORG, Hellenic Oncology Research Group; SCOT, Short Course Oncology Treatment; TOSCA, Three or Six Colon Adjuvant.
aLess than 12 lymph nodes examined (, 10 for SCOT).
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In the MOSAIC study, the addition of oxaliplatin to fluoro-
uracil (FU) improved 5-year DFS from 74.6% to 82.3%7 for
high-risk stage II. We set the noninferiority boundary HR at
1.2, equivalent to maintaining 60% of the benefit seen in
MOSAIC from adding oxaliplatin to FU. This difference
corresponds to accepting up to a 3.1% reduction in 5-year
DFS (82.3% in 6 m to 79.2% in 3 m FOLFOX or CAPOX).
542 DFS events were required to detect the noninferiority
HR of 1.2 for the 3- v 6-month arm with 80% power at a
one-sided type one error rate of 0.10. The significance level
of 0.10 was selected because the number of events re-
quired for the typical 0.025 could not be obtained in a
reasonable timescale even with a worldwide collaborative
effort like IDEA.
RESULTS
Between June 20, 2007, and January 31, 2017, a total of
3,332 patients with high-risk stage II colon and rectal
cancer were randomly assigned into the four studies. By the
time of statistical analysis (December 5, 2018), the median
DFS follow-up is 60.2 (59.8-60.5) months. The Consort
diagram (Fig 1) shows that 59 patients were excluded from
the mITT analysis, 35 because they did not receive any
1High-risk stage II colon or rectal cancer deemed at registration 


















35 patients who did not receive any FOLFOX and CAPOX


























46 patients whose stage was revised after 
enrollment:
• 18 stage I
• 22 stage III
• 6 stage missing
28 patients who do not have high-risk features










FIG 1. CONSORT diagram. ACHIEVE2, Adjuvant Chemotherapy for Colon Cancer with High Evidence2; CAPOX, capecitabine and oxaliplatin; FOLFOX,
fluorouracil, leucovorin, and oxaliplatin; HORG, Hellenic Oncology Research Group; mITT, modified intention-to-treat; RT, radiation therapy; SCOT, Short
Course Oncology Treatment; TOSCA, Three or Six Colon Adjuvant.
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chemotherapy and 24 patients with rectal cancer from
SCOT who had received preoperative short-course radio-
therapy. There were 3,273 patients in the mITT analysis of
whom 62% received CAPOX and 38% FOLFOX.
Patient details and tumor characteristics are presented in
Table 1. The percentage of T4 patients in the four studies
varied from 14% in HORG to 50% in SCOT. Similarly,
patients with poorly differentiated tumors varied from 12%
in ACHIEVE2 to 57% in HORG. Microsatellite instability
(MSI) data are not available. TOSCA recorded three vari-
ables (T4, poorly differentiated tumor, and inadequate
nodal harvest), whereas SCOT, ACHIEVE2, and HORG
recorded six variables (T4, poorly differentiated tumor,
inadequate nodal harvest, obstruction, perforation, and any
type of invasion). Patients with one or multiple risk factors
from the six risk factors recorded in the SCOT, ACHIEVE2,
and HORG studies are shown in the Protocol.
Patient characteristics are well balanced across the ran-
domized arms, and there are no large differences between
CAPOX and FOLFOX (Protocol).
Treatment Intensity
Treatment intensity data are shown in the Protocol. For
patients randomly assigned to receive 3-month treatment,
approximately 90% received all the planned treatment
compared with 65% receiving all the planned treatment in
those randomly assigned to receive 6-month treatment
(P , .0001). The median fluoropyrimidine dose intensity
was similar for CAPOX and FOLFOX dropping by ap-
proximately 8% from 6-month duration to 3-month duration
(P, .0001). Median oxaliplatin dose intensity dropped by a
greater amount for both FOLFOX (15%) and CAPOX (25%)
(P , .0001).
Adverse Events
Adverse events are shown in the Protocol. Overall, patients
randomly assigned to 6-month treatment had significantly
more adverse events than patients receiving 3-month
treatment, especially diarrhea, peripheral neuropathy,
hand and foot syndrome, and mucositis. Peripheral
neuropathy $ grade II was 13% and 36% for those re-
ceiving 3-month and 6-month treatments, respectively.
Efficacy
The Kaplan-Meier plot for DFS in themITT study population
is shown in Figure 2. Of the DFS events, 553 were observed
exceeding the 542 required for 80% power. Five-year DFS
for those receiving 3-month treatment was 80.7% and
83.9% for those receiving 6-month treatment (HR, 1.17;
80% CI, 1.05 to 1.31). As the CI crossed the noninferiority
HR of 1.2, noninferiority for 3-month treatment was not met
(P 5 .39). A sensitivity analysis in the confirmed high-risk
stage II patients gave virtually identical results.
There was no evidence of nonproportional hazards (P. .10
via assessment of Schoenfeld residuals) or of heterogeneity
in HRs across individual trials (Q-statistic [P value] 5 4.24
[.24]; I2 [P value] 5 29.28% [.55]).
There were four planned subgroup comparisons: chemo-
therapy regimen (CAPOX v FOLFOX), T-stage (T4 v T1-3),
poorly differentiated tumor (yes or no), and inadequate
DFS HR = 1.17
80% CI, 1.05 to 1.31
95% CI, 0.99 to 1.38

























83.9 (82.0 to 85.9%)
80.7 (78.6 to 82.7%)








1,639 1,493 1,318 1,137 938 668 415
1,634 1,492 1,331 1,156 946 693 405
FIG 2. Kaplan-Meier estimates of disease-free survival (DFS) for modified intention-to-treat study
population. HR, hazard ratio; NIF, noninferiority.
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nodal harvest. A Forest plot of the HRs in these subgroups
is shown in Figure 3. Choice of chemotherapy regimen was
the only group that showed a marked difference in the
duration effect. The HR for CAPOX was 1.02 (95% CI, 0.82
to 1.27), and the HR for FOLFOX was 1.41 (95% CI, 1.08 to
1.84). We had a preset significant level for interaction of
10%; therefore, the chemotherapy regimen achieved this in
the unadjusted analysis, but when the analysis was ad-
justed for multiple comparisons, this was not the case. In
view of the marked observed difference in HRs, the Kaplan-
Meier curves for CAPOX and FOLFOX are shown in Figure 4
along with 80% and 95% CIs.
An exploratory analysis of the effect of the number of high-
risk factors on DFS for the three studies (SCOT, ACHIEVE2,
and HORG) that collected data on six high-risk factors was
performed comparing those that had just one risk factor
and those with two or more risk factors. Kaplan-Meier
curves are shown in Figure 5A. Patients with two or
more risk factors had a significantly worse DFS (74.8%)
than those with just one risk factor (87.3%). The effect of
the chemotherapy regimen and the number of risk factors
are shown in Figure 5B. We were also able to show from all
four studies that high-risk stage II patients with T4 disease
have a worse outcome than those with T3 disease (Ap-
pendix Fig A1).
DISCUSSION
Patients with stage II colon cancer represent a heteroge-
neous group. Stage II patients benefit from adjuvant che-
motherapy treatment. The ACCENT adjuvant meta-
analysis8 looked at 20,898 patients in 18 adjuvant FU-
containing trials, 33% of which had stage II disease. This
showed an overall improvement in an 8-year survival of
5.4% (from 66.8% to 72.2%). Similarly, the QUASAR
study9 showed a 3.6% improvement in OS compared with
no adjuvant chemotherapy. In recent years, high-risk
features have been identified. These include T4 disease,
poorly differentiated tumors, bowel obstruction or bowel
aInteraction P value is larger than the Benjamini-Hochberg threshold; therefore, the interaction is not statistically
significant. b< 12 except for SCOT (< 10)
BH: Benjamini-Hochberg
Hazard Ratio


















































Favors 3 months Favors 6 months
FIG 3. Forest plot for preplanned subgroup analyses. CAPOX, capecitabine and oxaliplatin; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; HR, hazard
ratio; SCOT, Short Course Oncology Treatment.
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perforation, , 12 lymph nodes examined, and lympho-
vascular and perineural invasion. In stage II disease, only
patients with proficient mismatch repair benefit from FU
monotherapy in the adjuvant setting.10 A limitation to the
study is we do not have MSI data as MSI assessment only
became standard after completion of accrual to the studies.
This will be available in the future for some patients.
Stage II patients with proficient mismatch repair and any
risk factors should be considered for chemotherapy
treatment, which may include oxaliplatin. When these four
studies were conceived, there was evidence that the ad-
dition of oxaliplatin improved DFS by 3.8%.1 However,
more mature data showed no difference in OS for stage II
disease.5 With high-risk stage II disease, 5-year DFS was
increased from 74.6% to 82.3%, and OS at 6 years was
increased from 83.3% to 85.0% by the addition of oxali-
platin, but neither were statistically significant.
Although high-risk stage II features have been widely ac-
cepted, we do not know their relative impact on prognosis
or if any indicate which patients will benefit from adjuvant
chemotherapy. There is considerable variation in the
percentage of high-risk features between studies. Patients
with T4 disease ranged from 14% in the HORG study to
50% in the SCOT study, poorly differentiated tumors from
12% in the ACHIEVE2 study to 57% in the HORG study,
and patients with inadequate nodal harvest from 10% in the
SCOT study to 30% in the HORG study. The percentage of
patients receiving CAPOX varied from 39% in the TOSCA
study to 84% in the ACHIEVE2 study.
We did not know if having more than one risk factor resulted
in a worse prognosis, but an exploratory analysis using data
from three of these studies has shown that patients with two
or more risk factors have a significantly worse prognosis than
patients with only one risk factor. Only 130 patients had rectal
cancers (4% of total), and the applicability of the overall
results to this subgroup must be seen in the light of this.
The primary end point of this study showed 80.7% (95%CI,
78.6% to 82.7%) 5-year DFS with 3-month chemotherapy
and 83.9% (95% CI, 82.9% to 85.9%) with 6-month
treatment, with an absolute difference of 3.2%. The HR
was 1.17 (80% CI, 1.05 to 1.3), which crossed the non-
inferiority margin of 1.2, and so noninferiority was not
proven. We do not yet have sufficiently mature OS data as
for adjuvant treatment studies in high-risk stage II colon
cancer, at least a 6-year follow-up is recommended for an
accurate assessment of OS.11
There was a preplanned analysis looking at the following
variables: chemotherapy regimen, T4 disease (yes or no),
poorly differentiated tumor (yes or no), and if there had
been an inadequate nodal harvest (yes or no) (Fig 3). Of
these four variables, only chemotherapy regimen showed a
marked difference. This effect of chemotherapy regimen
was similar to that seen in the IDEA collaboration for stage
III colon cancer.4 Although the P value for interaction
between regimen and treatment duration was not statisti-
cally significant after adjustment for multiple testing, it is
worth noting that the 80% CI for CAPOX did not cross the
noninferiority margin (Fig 4A), while that for FOLFOX in-
dicates superiority for 6-month treatment.
When the high-risk stage II analysis results are considered
alongside the stage III results from the IDEA collaboration,
we have data from 16,107 patients, which clearly demon-
strates the effect on the duration of adjuvant chemotherapy
treatment is different for patients receiving CAPOX compared
DFS HR = 1.02
80% CI, 0.88 to 1.17
95% CI, 0.83 to 1.28
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DFS HR = 1.41
80% CI, 1.18 to 1.68
95% CI, 1.08 to 1.84












619 569 508 462 404 311 214
635 586 545 503 442 332 220
B
FIG 4. (A) Kaplan-Meier estimates of disease-free survival (DFS) among capecitabine and oxaliplatin (CAPOX)–treated patients and (B) Kaplan-Meier
estimates of DFS among fluorouracil, leucovorin, and oxaliplatin (FOLFOX)–treated patients. HR, hazard ratio; NIF, noninferiority.
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with those receiving FOLFOX. For CAPOX, 3-month treatment
is noninferior to 6-month treatment, but for FOLFOX,
chemotherapy of 6-month duration is superior to 3-month
treatment. Similarly, in high-risk stage II patients and stage
III patients, giving 6-month chemotherapy treatment results
in significantly more toxicity. This is especially true for
No. at risk
10 2 3 4 5 6
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NIF P value5-Year Rate (95% CI)Events/TotalHigh-Risk Group
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aInteraction P value is larger than the Benjamini-Hochberg threshold; therefore, the interaction is not
statistically significant
Hazard Ratio
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FIG 5. (A) Kaplan-Meier estimates of disease-free survival (DFS) for patients from Short Course Oncology Treatment
(SCOT), Adjuvant Chemotherapy for Colon Cancer with High Evidence2, and Hellenic Oncology Research Group
comparing those with one risk factor and those with two or more risk factors. (B) Forest plot for patients with one or two
or more high-risk factors and chemotherapy regimen received. CAPOX, capecitabine and oxaliplatin; FOLFOX,
fluorouracil, leucovorin, and oxaliplatin; HR, hazard ratio; NIF, noninferiority.
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neurotoxicity that has been shown to last for significant
periods of time and affect the quality of life.12,13
For patients with high-risk stage II disease receiving ad-
juvant chemotherapy, it is accepted that no OS benefit was
shown by the addition of oxaliplatin although an im-
provement in DFS was seen. We have demonstrated that
high-risk stage II patients with two or more risk factors
have a worse prognosis and those with T4 disease also
have a worse prognosis than those with T3 disease. In view
of this worse prognosis, patients with either T4 disease
and/or more than two risk factors could be considered for
combination treatment. If oxaliplatin-containing adjuvant
treatment is recommended in these patients, then the
balance between efficacy and toxicity has to be carefully
considered. Although noninferiority could not be dem-
onstrated for 3-month treatment in the overall study
population, the absolute difference in DFS between 3-
month and 6-month CAPOX treatment is only 0.3%, and
3-month treatment results in significantly less toxicity,
meaning that balancing efficacy and toxicity 3-month
CAPOX can be considered. However, for high-risk stage
II disease, adjuvant FOLFOX chemotherapy cannot be
recommended as 3-month treatment is inferior to 6-
month treatment, and 6-month treatment results in sig-
nificantly more toxicity, so taking into account, both re-
duced efficacy and increased toxicity FOLFOX
chemotherapy of any duration cannot be recommended.
The results of the IDEA collaboration on duration of ad-
juvant chemotherapy only apply to patients receiving an
oxaliplatin and fluoropyrimidine doublet. If patients with
high-risk stage II disease receive single-agent fluoropyr-
imidine treatment such as capecitabine, we have to
recommend the current standard duration of 6 months.
It should also be noted that the choice of 3 months of
FOLFOX as adequate treatment for low-risk stage III pa-
tients based on IDEA4 would seem inconsistent with the
results reported here for FOLFOX in high-risk stage II. We
also note that the trend for better outcome with longer
treatment duration for patients with T4 in IDEA is not re-
flected in these data. However, it should be noted that the
prognosis of patients with high-risk stage II cancers can be
worse than that for those with low-risk stage III cancers.14
Further research to better define the risk factors for high-risk
stage II disease and identify those patients who benefit from
adjuvant chemotherapy (especially combination chemo-
therapy) is needed. There is increasing evidence that cir-
culating tumor DNA can identify patients more likely to
relapse and hence potentially benefit from adjuvant che-
motherapy.15 Circulating tumor DNA assessment should be
in all future trials and may be helpful in deciding which stage
II patients receive chemotherapy.
It should be recognized that the noninferiority conclusion in
patients who received 3months of CAPOX in this analysis was
based on a less stringent control of false-positive rate of 10%
and subgroup findings. However, regimen-dependent sub-
group analyses were prospectively planned, and more im-
portantly, the results are highly consistent with that shown in
stage III population. IDEA has previously shown that 3-month
treatment with CAPOX has become a standard-of-care ad-
juvant chemotherapy for patients with stage III disease. Al-
though noninferiority has not been demonstrated in the overall
population, the convenience, reduced toxicity, and cost of 3-
month adjuvant CAPOX suggest that the standard of care for
high-risk stage II colon cancer can be considered to be either
3-month CAPOX (if considered for oxaliplatin-based chemo-
therapy) or 6-month single-agent fluoropyrimidine.
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APPENDIX
No. at risk























2.18 (1.82 to 2.60)73.7 (70.9 to 76.6%)264/1,082T4
Reference86.7 (85.1 to 88.2%)283/2164T3
HR (95% CI)5-Year Rate (95% CI)Events/TotalT-stage
2,164 2,017 1,818 1,577 1,318 982 615
1,082 947 812 700 555 372 203
FIG A1. Kaplan-Meier estimates of disease-free survival for patients with T3 disease compared to T4 disease.
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